Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Désirée Mfm van der HeijdeAtul A DeodharXenofon BaraliakosMatthew A BrownHiroaki DobashiMaxime DougadosDirk ElewautAlicia M EllisCarmen FleurinckKarl GaffneyLianne S GenslerNigil HaroonMarina MagreyWalter P MaksymowychAlexander MartenUte MassowMarga OortgiesenDenis PoddubnyyMartin RudwaleitJulie Shepherd-SmithTetsuya TomitaFilip E Van den BoschThomas VauxHuji XuPublished in: Annals of the rheumatic diseases (2023)
Dual inhibition of IL-17A and IL-17F with bimekizumab resulted in significant and rapid improvements in efficacy outcomes vs placebo and was well tolerated in patients with nr-axSpA and r-axSpA.